Clinical effect of aribulin combined with NP regimen in the treatment of patients with advanced breast cancer

doi:10.11958/20241897

Abstract

Abstract:

Objective To investigate the clinical effect of aribulin combined with vinorelbine+cisplatin (NP) regimen in the treatment of advanced breast cancer patients. Methods Eighty patients with advanced breast cancer were selected and divided into the conventional group (treated with chemotherapy using NP regimen) and the combined group (treated with aribulin combined with NP regimen), with 40 cases in each group. The clinical benefit rate (CBR), objective response rate (ORR) and overall efficacy of the two groups were compared. Patients were followed for 12 months. The progression-free survival (PFS) was recorded in the two groups of patients. Serum levels of vascular endothelial growth factor (VEGF) A, VEGFB and VEGFC before treatment and 4 cycles after treatment were detected by enzyme-linked immunosorbent assay (ELISA). Adverse reactions of patients were evaluated and graded according to common adverse event evaluation criteria. Results The ORR and CBR of the combined group were significantly higher than those of the conventional group, and the overall curative effect of the combined group was better than that of the conventional group (P<0.05). PFS in the combination group was longer than that in the conventional group (P<0.01). After treatment, the levels of VEGFA, VEGFB and VEGFC in the 2 groups were lower than those before treatment, and the levels in the combined group were significantly lower than those in the conventional group (P<0.05). The main adverse reactions of 2 groups during treatment were grade Ⅰ to Ⅱ, including neutropenia, gastrointestinal reaction, peripheral nerve abnormality, fatigue, liver function injury and alopecia, with no statistical significance. Conclusion Aribulin combined with NP regimen in the treatment of advanced breast cancer can increase CBR and decrease VEGF expression level, with good safety.

Key words: breast neoplasms, vinorelbine, cisplatin, vascular endothelial growth factors, Eribulin, clinical benefit rate

CLC Number:

R737.9，R979.19

Figures/Tables 4

References 23

[1]	SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer Statistics,2021[J]. CA Cancer J Clin, 2021, 71(4):7-33. doi:10.3322/caac.21654.
[2]	李良强. 吉西他滨联合长春瑞滨与顺铂治疗蒽环类、紫杉醇类耐药的局部晚期或晚期乳腺癌的近期疗效[J]. 临床合理用药, 2023, 16(32):95-98.
	LI L Q. Short-term efficacy of gemcitabine combined with vinorelbine and cisplatin in the treatment of locally advanced or advanced breast cancer resistant to anthracycline and paclitaxel[J]. Chin of Clinical Rational Drug Use, 2023, 16(32):95-98. doi:10.15887/j.cnki.13-1389/r.2023.32.028.
[3]	魏玲, 王燕, 王培, 等. 艾立布林治疗晚期乳腺癌的临床疗效分析[J]. 中国肿瘤外科杂志, 2023, 15(1):36-39.
	WEI L, WANG Y, WANG P, et al. Clinical efficacy of Eribulin in the treatment of advanced breast cancer[J]. Chin J Surg Oncol, 2023, 15(1):36-39. doi:10.3969/j.issn.1674-4136.2023.01.007.
[4]	YUAN P, HU X, SUN T, et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer:A randomised clinical trial[J]. Eur J Cancer, 2019, 112:57-65. doi:10.1016/j.ejca.2019.02.002.
[5]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J]. 中国癌症杂志, 2019, 29(8):609-679.
	Breast cancer Professional Committee of Chinese Anti-Cancer Association. Guidelines and norms for diagnosis and treatment of breast cancer of Chinese Anticancer Association(2019 edition)[J]. China Oncology, 2019, 29(8):609-679. doi:10.19401/j.cnki.1007-3639.2019.08.009.
[6]	SCHWARTZ L H, LITIÈRE S, DE VRIES E, et al. RECIST 1.1-Update and clarification:From the RECIST committee[J]. Eur J Cancer, 2016, 62:132-137. doi:10.1016/j.ejca.2016.03.081.
[7]	DUECK A C, MENDOZA T R, MITCHELL S A, et al. Validity and reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events(PRO-CTCAE)[J]. JAMA Oncol, 2015, 1(8):1051-1059. doi:10.1001/jamaoncol.2015.2639.
[8]	王健宇, 许守平. 美国国家综合癌症网络临床实践指南:乳腺癌更新解读(2023V4)[J]. 中国肿瘤外科杂志, 2023, 15(3):214-218.
	WANG J Y, XU S P. Interpretation of updated NCCN clinical practice guidelines for breast cancer(2023V4)[J]. Chinese Journal of Surgical Oncology, 2023, 15(3):214-218. doi:10.3969/j.issn.1674-4136.2023.03.002.
[9]	XI J, OZA A, THOMAS S, et al. Retrospective analysis of treatment patterns and effectiveness of palbociclib and subsequent regimens in metastatic breast cancer[J]. J Natl Compr Canc Netw, 2019, 17(2):141-147. doi:10.6004/jnccn.2018.7094.
[10]	吕剑虹, 李俏, 张金涛, 等. 艾立布林单药或联合方案治疗晚期乳腺癌临床疗效和安全性分析[J]. 肿瘤综合治疗电子杂志, 2022, 8(3):103-107.
	LV J H, LI Q, ZHANG J T, et al. Analysis of the efficacy and safety of eribulin alone or combination regimen in the treatment of metastatic breast cance[J]. Journal of Multidisciplinary Cancer Management(Electronic Version), 2022, 8(3):103-107. doi:10.12151/JMCM.2022.03-12.
[11]	孔攀, 薛艺萌, 张莹莹, 等. 长春瑞滨联合顺铂治疗晚期三阴性乳腺癌效果观察[J]. 河南外科学杂志, 2019, 25(3):46-48.
	KONG P, XUE Y M, ZHANG Y Y, et al. Changchun rui marina combined cisplatin three negative treatment of advanced breast cancer effect observation[J]. Henan Journal of Surgery, 2019, 25(3):46-48.
[12]	余奎杨, 刘攀, 张浩文, 等. LncRNA ZFAS1靶向miR-373导致肝癌细胞顺铂耐药的机制研究[J]. 天津医药, 2022, 50(5):455-460.
	YU K Y, LIU P, ZHANG H W, et al. Study on the mechanism of LncRNA ZFAS1 targeting miR-373 to induce cisplatin resistance in hepatocellular carcinoma cells[J]. Tianjin Med J, 2022, 50(5):455-460. doi:10.11958/20203618.
[13]	李健斌, 江泽飞. 2021年中国临床肿瘤学会乳腺癌诊疗指南更新要点解读[J]. 中华医学杂志, 2021, 101(24):1835-1838.
	LI J B, JIANG Z F. Chinese Society of Clinical Oncology Breast Cancer Guideline version 2021:updates and interpretation[J]. National Medical Journal of China, 2021, 101(24):1835-1838. doi:10.3760/cma.j.cn112137-20210421-00954
[14]	FUNAHASHI Y, OKAMOTO K, ADACHI Y, et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models[J]. Cancer Sci, 2014, 105(10):1334-1342. doi:10.1111/cas.12488.
[15]	穆轶, 缪玮, 朱彧. 艾立布林治疗乳腺癌的临床研究进展[J]. 中国新药与临床杂志, 2022, 41(6):331-337.
	MU Y, MIAO W, ZHU Y. Clinical research progress of eribulin in treatment of breast cancer[J]. Chin J New Drugs Clin Rem, 2022, 41(6):331-337. doi:10.14109/j.enki.xyylc.2022.06.03.
[16]	TWELVES C, ANTHONEY A, SAVULSKY C I, et al. A phase 1b/2,open-label,dose-escalation,and dose-confirmation study of eribulin mesilate in combination with capecitabine[J]. Br J Cancer, 2019, 120(6):579-586. doi:10.1038/s41416-018-0366-5.
[17]	李永飞, 杨登元, 杨帆, 等. 艾立布林治疗晚期乳腺癌患者的临床疗效及不良反应分析[J]. 成都医学院学报, 2022, 17(2):170-173.
	LI Y F, YANG D Y, YANG F, et al. Efficacy and safety of Eribulin in advanced breast cancer[J]. Journal of Chengdu Medical College, 2022, 17(2):170-173. doi:10.3969/j.issn.1674-2257.2022.02.008.
[18]	ZHAO Y, XIE N, LI W, et al. Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China:a multicenter retrospective study[J]. Ther Adv Med Oncol, 2021,13:17588359211030210. doi:10.1177/17588359211030210.
[19]	桑蝶, 宋丽华, 邸立军, 等. 艾立布林治疗晚期乳腺癌疗效和安全性的多中心真实世界研究[J]. 中华肿瘤杂志, 2022, 44(4):364-369.
	SANG D, SONG L H, DI L J, et al. A multicenter real-world study of the efficacy and safety of Iribrin in the treatment of advanced breast cancer[J]. Chin J Oncol, 2022, 44(4):364-369. doi:10.3760/cma.j.cn112152-20210226-00173.
[20]	谭越, 李纲, 李雪莲, 等. 贝伐珠单抗联合紫杉醇治疗晚期乳腺癌的疗效及对患者免疫功能的影响[J]. 医学临床研究, 2023, 40(8):1132-1135.
	TAN Y, LI G, LI X L, et al. Efficacy of Bevacizumab combined with paclitaxel and its effect on patients' immune function in the treatment of advanced breast cancer[J]. Journal of Clinical Research, 2023, 40(8):1132-1135. doi:10.3969/j.issn.1671-7171.2023.08.004.
[21]	赵盼, 桑蝶, 王依盟, 等. 艾立布林治疗多线化疗失败晚期软组织肉瘤患者的疗效和安全性[J]. 癌症进展, 2022, 20(5):457-460.
	ZHAO P, SANG D, WANG Y M, et al. Efficacy and safety of Aribulin in the treatment of patients with advanced soft tissue sarcoma after failure of multi-line chemotherapy[J]. Oncology Progress, 2022, 20(5):457-460. doi:10.11877/j.issn.1672-1535.2022.20.05.07.
[22]	DE MATTOS-ARRUDA L, CORTES J, BLANCO-HEREDIA J, et al. The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. NPJ Breast Cancer[J]. NPJ Breast Cancer, 2021, 7(1):73. doi:10.1038/s41523-021-00282-0.
[23]	郭曦, 游洋, 庄荣源, 等. 艾立布林单药或联合方案治疗晚期成人软组织肉瘤的疗效及安全性分析[J]. 实用肿瘤杂志, 2021, 36(5):406-411.
	GUO X, YOU Y, ZHUANG R Y, et al. Efficacy and safety of eribulin or combination regimen in treatment of advanced adult soft tissue sarcoma[J]. Journal of Practical Oncology, 2021, 36(5):406-411. doi:10.13267/j.cnki.syzlzz.2021.082.

组别	年龄/岁				病理类型												病理分期
组别	年龄/岁				导管内乳头状癌			浸润性导管癌			浸润性小叶癌			髓样癌			初始Ⅳ期			复发转移
常规组	51.82±8.42				10（25.0）			15（37.0）			9（22.5）			6（15.0）			7（17.5）			33（82.5）
联合组	52.50±8.86				9（22.5）			14（35.0）			12（30.0）			5（12.5）			5（12.5）			35（87.5）
χ²或t	0.349				0.607												0.392
组别		内脏转移					分子分型								治疗线数
组别		有		无			HR+/HER2-			HR-/HER2-			HER2+		2			3			>3
常规组		32（80.0）		8（20.0）			28（70.0）			10（25.0）			2（5.0）		12（5.0）			16（5.0）			12（5.0）
联合组		30（75.0）		10（25.0）			26（65.0）			12（30.0）			2（5.0）		14（5.0）			11（5.0）			15（5.0）
χ²		0.287					0.256								1.413
组别			转移部位
组别			骨			肝			肺			胸壁				脑			淋巴结
常规组			24（60.0）			21（52.5）			13（32.5）			10（25.0）				5（12.5）			19（47.5）
联合组			26（65.0）			22（55.0）			16（40.0）			8（20.0）				4（10.0）			21（52.5）
χ²			0.213			0.050			0.487			0.287				0.125			0.200

组别	年龄/岁				病理类型												病理分期
组别	年龄/岁				导管内乳头状癌			浸润性导管癌			浸润性小叶癌			髓样癌			初始Ⅳ期			复发转移
常规组	51.82±8.42				10（25.0）			15（37.0）			9（22.5）			6（15.0）			7（17.5）			33（82.5）
联合组	52.50±8.86				9（22.5）			14（35.0）			12（30.0）			5（12.5）			5（12.5）			35（87.5）
χ²或t	0.349				0.607												0.392
组别		内脏转移					分子分型								治疗线数
组别		有		无			HR+/HER2-			HR-/HER2-			HER2+		2			3			>3
常规组		32（80.0）		8（20.0）			28（70.0）			10（25.0）			2（5.0）		12（5.0）			16（5.0）			12（5.0）
联合组		30（75.0）		10（25.0）			26（65.0）			12（30.0）			2（5.0）		14（5.0）			11（5.0）			15（5.0）
χ²		0.287					0.256								1.413
组别			转移部位
组别			骨			肝			肺			胸壁				脑			淋巴结
常规组			24（60.0）			21（52.5）			13（32.5）			10（25.0）				5（12.5）			19（47.5）
联合组			26（65.0）			22（55.0）			16（40.0）			8（20.0）				4（10.0）			21（52.5）
χ²			0.213			0.050			0.487			0.287				0.125			0.200

组别	n	CR	PR	SD	PD
常规组	40	0	4（10.0）	12（30.0）	24（60.0）
联合组	40	0	11（27.5）	14（35.0）	15（37.5）
Z		2.284^＊

组别	n	CR	PR	SD	PD
常规组	40	0	4（10.0）	12（30.0）	24（60.0）
联合组	40	0	11（27.5）	14（35.0）	15（37.5）
Z		2.284^＊

组别	VEGFA
组别	治疗前	治疗后	t
常规组	284.74±31.90	125.31±13.51	30.179^＊＊
联合组	287.28±31.52	93.28±10.66	37.128^＊＊
t	0.358	11.772^＊＊
组别	VEGFB
组别	治疗前	治疗后	t
常规组	313.06±32.31	216.21±23.08	14.470^＊＊
联合组	311.24±34.25	142.65±16.44	29.654^＊＊
t	0.245	16.419^＊＊
组别	VEGFC
组别	治疗前	治疗后	t
常规组	200.12±23.75	143.36±16.89	10.882^＊＊
联合组	201.88±23.02	89.62±10.03	27.728^＊＊
t	0.336	17.308^＊＊